Methocarbamol vs Oxybutynin for Pain After Kidney Stone Procedure

This trial tests two medicines, methocarbamol and oxybutynin, to determine which better reduces pain from a stent after a kidney stone procedure. A ureteral stent, placed post-procedure, often causes discomfort and bladder spasms. Methocarbamol, a muscle relaxant, might ease these spasms without the side effects commonly associated with oxybutynin, which currently relaxes bladder muscles. Individuals who have undergone ureteroscopy with a stent and experience post-procedure pain may be suitable for this trial. As an unphased trial, this study provides a unique opportunity to contribute to research that could enhance post-procedure comfort for future patients.

The trial protocol does not specify if you must stop taking your current medications. However, you must be willing to take only diclofenac (or tramadol if you can't take diclofenac), phenazopyridine, and acetaminophen for post-stent placement discomfort.

The trial requires participants to take only specific medications for pain control after the procedure, including diclofenac (or tramadol if diclofenac is not suitable), phenazopyridine, and acetaminophen. You may need to stop other pain medications, but the protocol does not specify about other types of medications.

Research shows that methocarbamol is usually well-tolerated and relieves muscle spasms. Some people experience mild side effects such as sleepiness, dizziness, or nausea. Those with kidney or liver problems should exercise caution, as the medication might remain in the body longer.

Oxybutynin treats an overactive bladder by relaxing bladder muscles. While it reduces bladder spasms, it can cause side effects like dry mouth, constipation, and blurred vision. Some studies suggest it may also reduce the need for painkillers after surgery.

Researchers are excited about these treatments because they offer alternative approaches for managing pain after kidney stone procedures. Methocarbamol is a muscle relaxant that targets muscle spasms, which can be a source of discomfort following ureteroscopy. On the other hand, Oxybutynin is traditionally used for bladder issues and works by relaxing bladder muscles, potentially easing pain by reducing spasms in the urinary tract. Both treatments provide a different mechanism of action compared to standard pain management options like opioids or NSAIDs, and they may help minimize the need for stronger pain medications with more side effects.

This trial will compare the effectiveness of Methocarbamol and Oxybutynin for pain management after kidney stone surgery. Research has shown that Methocarbamol, a muscle relaxant, may ease pain from ureteral stents by calming nerve signals and possibly blocking certain channels, reducing muscle spasms. Participants in one arm of the trial will receive Methocarbamol. Oxybutynin, another medication under study, is often used to treat an overactive bladder by relaxing bladder muscles. Studies have found that Oxybutynin can effectively reduce bladder spasms and pain from ureteral stents, though it may cause side effects like dry mouth and constipation. Participants in another arm of the trial will receive Oxybutynin. The trial aims to compare the effectiveness of both treatments to determine the best way to reduce pain and discomfort after kidney stone surgery.¹²⁶⁷⁸